Pipeline

Pipeline

SalubRx Therapeutics Inc. has a pipeline of clinical and preclinical New Chemical Entities (NCEs) as clinical leads, back-ups and new developments. Characteristic profiles and properties: Biopharmaceutics Classification System (BCS) 1, low Cost of Goods, API stability up to 3 years, 90 day primate toxicology with minimal findings and safety in elderly patients.

Compound Indications Selectivity Stage
SBX-413 Parkinson's Dyskinesia nNOS Pre-IND
SBX-613 Parkinson's Dyskinesia (backup) nNOS Pre-Clin
SBX-677 Parkinson's Dyskinesia / Neurodegeneration nNOS/iNOS Pre-Clin
SBX-774 Parkinson's Dyskinesia / Neurodegeneration (backup) nNOS/iNOS Discovery

CoM composition of matter patent; others possible